Table 1.

Melanoma patient characteristics and assay details.

Patient ID	Agea	Sex	Stage of Diseaseb	Biological Samplesc
1	70.2	M	III	PBMCd	TILNd
2	44.6	M	IV	PBMCd,e	TILd
3	36.4	M	IV	PBMCe	n/d
4	36.3	M	IV	PBMCe	n/d
5	55.5	M	IV	PBMCd,e	TILd
9	71.3	M	IV	PBMCd	TIL-1d TIL-2d
11f	58.1	F	IV	PBMC-1d PBMC-2d,e	TILd,e
13g	69.6	M	IV	PBMCd,e	TILN-1d,e TILN-2d,e
16	45.8	M	III	PBMCd,e	TILd,e
17	81.3	M	IV	n/d	TILe
18	54.8	F	IV	PBMCd	TILNd
19	60.3	M	IV	PBMCe	n/d
20	57.0	M	III	PBMCe PBMC (Baseline)h PBMC (Post-IT-AG)h PBMC (Post-Ipi-1)h PBMC (Post-Ipi-2)h PBMC (Post-Ipi-3)h	TIL (T-T-0)h,i

^aAge at time of initial blood sample acquisition for all patients except Patient 17, which refers to the age at time of tumor resection.

^bAJCC stage refers to the stage of disease at the time of initial blood sample acquisition for all except Patient 17, which refers to the stage of disease at the time of tumor resection.

^cPBMC were obtained near the time of clinically indicated surgery to obtain TIL or TILN for Patients 1, 2, 3, 4, 5, 9, 11, 13, 16, 17, 18, and 19, or at several timepoints beginning 20 months after resection of an in-transit metastasis (Patient 20).

^dTRB Sanger sequencing.

^eMAA peptide pentamer flow cytometry; Patients were HLA-A2⁺, except Patients 1 and 9.

^fTwo blood samples collected ~2 year apart.

^gTwo anatomically distinct TIL obtained on the same date.

^hTRB Illumina sequencing.

^IIFN-γ ICS.

AJCC, American Joint Committee on Cancer; PBMC, Peripheral blood mononuclear cells; TIL, tumor-infiltrating lymphocytes; TILN, tumor-infiltrated lymph node n/d, sample not analyzed